


Reference Data

(Consolidated Financial Results for Q4 FY2011)



Daiichi-Sankyo

May 11, 2012

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Management / Financial Indicators	P8
8.	Capital Expenditure and Depreciation Expenses	P8
9.	Consolidated Balance Sheets	P9
10.	Consolidated Statements of Cash Flow	P11
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

Summary of Product Outlines

1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			FY2011				FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to sales	Forecast	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%	100%	980.0	41.3	+4.4%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%	30%	297.0	28.4	+10.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%	70%	683.0	12.9	+1.9%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%	59%	583.0	11.1	+1.9%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%	20%	193.0	7.9	+4.3%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%		not disclosed		
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%		not disclosed		
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%		not disclosed		
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%	10%	100.0	1.8	+1.8%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6			0.0	22.0	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2			not disclosed		
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4			not disclosed		
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%	10%	100.0	23.8	+31.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0			-5.0	37.3	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0			not disclosed		
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9			not disclosed		
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%	10%	95.0	61.1	+180.1%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8			45.0	21.5	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0			not disclosed		
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7			not disclosed		
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%	5%	50.0	39.6	+381.6%
Effective tax rate		37%			34%			-			-			117%						
Overseas sales ratio results		51%			48%			45%			56%			50%						

Notes to FY2011 Results Year-on-Year Comparisons

Net Sales	Memory +9.8, Loxonin +6.9, Plexxikon +5.9, Prasugrel alliance revenue +5.7, Nexium +3.9, Ranbaxy +3.6 Return of sales rights -24.0, Levofloxacin -16.7, Luitpold -9.2, Pravastatin -5.7, Denosumab milestone payment -5.5 (appreciation of JPY to USD and EUR -18.5, appreciation of JPY to INR -20.5)
R&D expenses	Forex impact (appreciation of JPY to USD, EUR, and INR) -7.0, Nexium in-license cost -8.2
Other expenses	Forex Impact (appreciation of JPY to USD, EUR, and INR) -18.0, Cost increase from new subsidiaries including Plexxikon and Kitasato Daiichi Sankyo Vaccine and new product launches
Non-operating items	Increase in "forex losses" and "loss on valuation of derivatives" of Ranbaxy
Extraordinary losses	Provision for settlement expenses (Ranbaxy's provision in connection with the investigations by the U.S. Department of Justice)
Income taxes	Decrease in income before income taxes and minority interests Special factors below worsened the effective tax rate Provision for settlement expenses not tax deductible Reversal in deferred tax asset following the cut in income tax rate in Japan
Minority interests	Minority interests on provision for settlement expenses

Notes to FY2012 Forecast Year-on-Year Comparisons

Net Sales	Japan Company +40.2 (new products +46.3), Daiichi Sankyo Healthcare +2.1 Ranbaxy +3.5, Asia, South and Central America (ASCA) +9.4, Others +4.1 (sales increase from Japan Vaccine launch, etc) 3 companies in U.S. and Europe -18.0 (Olmesartan, etc)
SG&A expenses	New product launches in Japan (+), Plexxikon (+), key R&D projects (+) cost increase(+)/decrease(-) Cutting expenses in overseas businesses (-)
Extraordinary items	Extraordinary losses 5.0 (removal costs for non-current assets, etc)

2. Currency Rate

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011		FY2012
	Results	Results	Results	Results	Results	YoY	Forecast
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65	80.00
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17	100.00
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20	1.70

Appreciation of JPY to USD and EUR negatively affected the FY2011 Q4 YTD results by 39 bil yen in net sales and 4 bil yen in operating income.
Annual impact of one yen change is estimated to affect the group's FY2012 performance by; USD: net sales 2 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income minor

3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%

Ranbaxy Group

Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-

Inter-segment Transactions

Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units

	FY2011		Q1			Q2			Q3			Q4			FY2011			FY2012	
	Plan *1	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
JPY Bn																			
Consolidated Net Sales	970.0	+0.3%	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%	980.0	+4.4%
Japan Company (domestic sales)	435.0	+4.6%	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%	450.0	+9.8%
Olmotec	93.0	+13.0%	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%	81.0	+0.1%
Rezaltas	17.0	+264.3%	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%	19.0	+41.2%
Calblock	15.0	+7.5%	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%	13.0	+5.0%
Loxonin	58.0	+7.1%	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%	62.0	+1.6%
Cravit	38.0	+17.4%	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%	37.0	+1.8%
Nexium	not disclosed	-	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-	29.0	+642.5%
Memya	not disclosed	-	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-	26.0	+164.3%
Mevalotin	32.0	-15.9%	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%	26.0	-21.4%
Artist	23.0	-3.0%	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%	21.0	-14.4%
Omnipaque	23.0	-8.0%	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%	18.0	-23.5%
Urief	11.0	+9.4%	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%	11.0	+0.1%
Inavir	9.0	+35.6%	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%	10.0	-6.8%
New Ranmark	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.0	-
Vaccines	not disclosed	-	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-	not disclosed	-
Daiichi Sankyo Espha products	not disclosed	-	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-	not disclosed	-
Daiichi Sankyo Healthcare (OTC)	49.0	+9.3%	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%	48.0	+4.6%
Daiichi Sankyo, Inc. (US)	130.0	-0.4%	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%	115.0	-9.5%
Olmesartan	88.0	-6.8%	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%	71.0	-19.2%
Benicar/Benicar HCT	67.0	-15.9%	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%	54.0	-24.2%
Azor	13.5	+1.5%	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%	11.0	-8.6%
Tribenzor	7.5	+415.9%	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%	6.0	+30.0%
Welchol	32.0	+12.2%	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%	31.0	+15.4%
Effient (alliance revenue)	not disclosed	-	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-	not disclosed	-
Luitpold Pharmaceuticals, Inc. (US)	49.0	-9.1%	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%	44.0	-1.7%
Venofer	25.0	-18.5%	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%	23.0	-7.4%
Daiichi Sankyo Europe GmbH	77.0	+15.9%	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%	65.0	-7.4%
Olmesartan	55.0	+19.1%	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%	48.0	-5.9%
Olmotec/Olmotec Plus	40.0	+9.0%	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%	34.0	-7.2%
Sevikar	12.0	+43.1%	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%	10.0	-8.9%
Sevikar HCT	3.0	+172.3%	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%	4.0	+18.3%
Efient (alliance revenue)	not disclosed	-	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-	not disclosed	-

	FY2011		Q1			Q2			Q3			Q4			FY2011			FY2012		
	Plan *1	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY	
Asia, South and Central America (ASCA) 2	30.0	+9.3%	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%		38.0	+33.0%
Daiichi Sankyo Pharmaceutical (Beijing)	not disclosed	-	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-	not disclosed	-	-
Daiichi Sankyo Pharmaceutical (Shanghai)	not disclosed	-	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-	not disclosed	-	-
Daiichi Sankyo Taiwan	not disclosed	-	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-	not disclosed	-	-
Daiichi Sankyo Korea	not disclosed	-	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-	not disclosed	-	-
Daiichi Sankyo (Thailand)	not disclosed	-	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-	not disclosed	-	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	-	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-	not disclosed	-	-
Daiichi Sankyo Venezuela	not disclosed	-	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-	not disclosed	-	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	-	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-	not disclosed	-	-
Ranbaxy Laboratories Limited	162.0	-5.8%	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%		179.0	+2.0%
Others	38.0	-32.5%	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%		41.0	+11.1%
Levofloxacin export, royalty, etc	7.0	-75.1%	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%		3.0	-63.2%
Plexikon	not disclosed	-	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-	not disclosed	-	-

Currency rates for overseas subsidiaries

	Plan	Q1 Results	Q2 YTD Results	Q3 YTD results	Q4 YTD Results	FY2011 Results	FY2012 Forecast
USD/JPY (average)	83.00	81.75	79.81	79.00	79.07	79.07	80.00
EUR/JPY (average)	115.00	117.40	113.78	110.62	108.96	108.96	100.00
INR/JPY (average)	1.90	1.83	1.83	1.79	1.73	1.73	1.70

New Product Launches

May 2011: Sprix (analgesic and anti-inflammatory drug) lunched in US. Sales of Sprix are included in "Luitpold".

Jun 2011: Memary (treatment for Alzheimer's Disease) launched in Japan.

Jul 2011: Lixiana (direct oral factor Xa inhibitor for the prevention of venous thromboembolism after major orthopedic surgery) launched in Japan. Sales of Lixiana are included in "Japan Company (domestic sales)".

Aug 2011: Zelboraf (personalized treatment for melanoma) launched in US. Zelboraf related revenue are / will be included in Plexikon under "Others".

Sep 2011: Nexium (proton pump inhibitor for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, etc) launched in Japan.

Apr 2012: Ranmark (anti-RANKL antibody for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors) launched in Japan.

Notes

*1 2011 Plan are those announced at the beginning of the fiscal year (May 2011)

*2 Since companies in China, Brazil, Venezuela and Mexico will change their fiscal year-ends from December to March, their FY2012 financial results will be for 15 months.

[Reference] Sales in Local Currency

	FY2011		Q1			Q2			Q3			Q4			FY2011			FY2012	
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
USD Mn																			
Daichi Sankyo, Inc. (US)	1,566	+2.9%	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%	1,438	-10.6%
Olmesartan	1,060	-3.8%	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%	888	-20.2%
Benicar/Benicar HCT	807	-13.2%	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%	675	-25.1%
Azor	163	+4.8%	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%	138	-9.6%
Tribenzor	90	+432.8%	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%	75	+28.5%
Welchol	386	+15.9%	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%	388	+14.1%
Effient (alliance revenue)	not disclosed	-	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-	not disclosed	-
USD Mn																			
Luitpold Pharmaceuticals, Inc. (US)	590	-6.1%	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%	550	-2.8%
Venofor	301	-15.8%	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%	288	-8.5%
EUR Mn																			
Daiichi Sankyo Europe GmbH	670	+14.1%	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%	650	+0.9%
Olmesartan	478	+17.2%	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%	480	+2.5%
Olmotec/Olmetec Plus	348	+7.3%	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%	340	+1.1%
Sevikar	104	+40.8%	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%	100	-0.7%
Sevikar HCT	26	+167.9%	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%	40	+28.9%
Efient (alliance revenue)	not disclosed	-	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-	not disclosed	-
INR Bn																			
Ranbaxy Laboratories Limited	85	-4.6%	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%	105	+3.8%

5. Sales of Global Products

	FY2011		Q1			Q2			Q3			Q4			FY2011			FY2012	
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
JPY Bn																			
Olmesartan	270.0	+11.8%	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%	237.0	-5.1%
Olmetec (JPN)	93.0	+13.0%	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%	81.0	+0.1%
Rezaltas (JPN)	17.0	+264.3%	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%	19.0	+41.2%
Benicar/Benicar HCT (US)	67.0	-15.9%	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%	54.0	-24.2%
Azor (US)	13.5	+1.5%	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%	11.0	-8.6%
Tribenzor (US)	7.5	+415.9%	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%	6.0	+30.0%
Olmetec/Olmetec Plus (EU)	40.0	+9.0%	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%	34.0	-7.2%
Sevikar (EU)	12.0	+43.1%	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%	10.0	-8.9%
Sevikar HCT (EU)	3.0	+172.3%	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%	4.0	+18.3%
Other subsidiaries, export, etc	17.0	+22.0%	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%	18.0	+9.2%
Levofloxacin	53.0	-23.3%	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%	49.0	-6.5%
Cravit (JPN)	38.0	+17.4%	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%	37.0	+1.8%
Export, royalty, etc	7.0	-75.1%	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%	3.0	-63.2%
Other subsidiaries	8.0	-7.7%	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%	9.0	+13.6%
Pravastatin	38.0	-15.3%	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%	32.0	-18.3%
Mevalotin (JPN)	32.0	-15.9%	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%	26.0	-21.4%
Other subsidiaries, export, etc	6.0	-11.9%	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%	6.0	-1.6%
Prasugrel	not disclosed	-	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-	not disclosed	-
Effient alliance revenue (US)	not disclosed	-	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-	not disclosed	-
Efient alliance revenue (EU)	not disclosed	-	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-	not disclosed	-

6. Number of Employees

	Mar 2011 Results	Jun 2011 Results	Sep 2011 Results	Dec 2011 Results	Mar 2012 Results
Total Number of Employees	30,488	31,556	31,572	31,608	31,929
Japan	9,002	9,402	9,359	9,391	9,308
* Overseas	21,486	22,154	22,213	22,217	22,621
Daiichi Sankyo Group	17,065	17,771	17,777	17,884	17,877
* Ranbaxy Group	13,423	13,785	13,795	13,724	14,052

* For overseas subsidiaries with different fiscal year-ends, numbers as of Dec-end are shown in the Mar-end columns

7. Management / Financial Indicators

	FY2009 Results	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Results	FY2012 Forecast
Management Indicators					
Earnings per share (EPS)	59.5 Yen	99.6 Yen	52.6 Yen	14.8 Yen	71.0 Yen
Dividend per share	60.0 Yen	60.0 Yen	30.0 Yen	60.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	100.9 %	60.2 %	57.0 %	406.8 %	84.5 %
Return on equity (ROE)	4.9 %	8.2 %	- %	1.3 %	
Dividend on equity (DOE)	4.9 %	5.0 %	- %	5.1 %	
Book value per share (BPS)	1,215.6 Yen	1,206.1 Yen	1,196.1 Yen	1,174.8 Yen	
Equity ratio	57.4 %	57.4 %	57.2 %	53.0 %	
Number of treasury stock purchased	-	-	-	-	
Total number of common shares	704 million	704 million	704 million	704 million	
Share price at end of period	1,751 Yen	1,606 Yen	1,620 Yen	1,508 Yen	
Market value	1,232.6 JPY Bn	1,130.4 JPY Bn	1,140.3 JPY Bn	1,069.2 JPY Bn	
Financial Indicators					
Total assets	1,489.5 JPY Bn	1,480.2 JPY Bn	1,472.2 JPY Bn	1,518.5 JPY Bn	
Current assets	819.8 JPY Bn	894.1 JPY Bn	788.0 JPY Bn	861.5 JPY Bn	
*1 Liquidity on hand	358.3 JPY Bn	426.8 JPY Bn	299.7 JPY Bn	324.3 JPY Bn	
Debt with interest	290.9 JPY Bn	299.4 JPY Bn	260.7 JPY Bn	275.9 JPY Bn	
Equity capital	855.7 JPY Bn	849.0 JPY Bn	842.0 JPY Bn	804.9 JPY Bn	
Cash flow from operating activities	130.2 JPY Bn	141.1 JPY Bn	46.0 JPY Bn	92.6 JPY Bn	
Cash flow from investing activities	42.6 JPY Bn	-63.0 JPY Bn	-84.8 JPY Bn	-125.1 JPY Bn	
Cash flow from financial activities	-89.1 JPY Bn	-26.0 JPY Bn	-50.3 JPY Bn	-50.2 JPY Bn	
*2 Free cash flow	172.9 JPY Bn	78.2 JPY Bn	-38.8 JPY Bn	-32.5 JPY Bn	
Cash and cash equivalents, end of period	259.2 JPY Bn	302.4 JPY Bn	205.1 JPY Bn	212.7 JPY Bn	
Others					
Number of consolidated subsidiaries	99	101	102	103	

*1 Current deposits + marketable securities + investment securities, etc

*2 Cash flow from operating activities and investing activities

8. Capital Expenditure and Depreciation and Amortization Expenses

	FY2009 Results	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Results	FY2012 Plan
Capital expenditure	29.7 JPY Bn	37.3 JPY Bn	20.4 JPY Bn	62.9 JPY Bn	55.0 JPY Bn
Depreciation and amortization expense	45.9 JPY Bn	43.9 JPY Bn	21.8 JPY Bn	46.3 JPY Bn	42.0 JPY Bn
Tangible assets	28.8 JPY Bn	27.5 JPY Bn	13.6 JPY Bn	29.4 JPY Bn	
Intangible assets	17.1 JPY Bn	16.5 JPY Bn	8.2 JPY Bn	16.8 JPY Bn	

9. Consolidated Balance Sheets

(Millions of yen*)

	Mar 2011	Mar 2012	YoY	Notes
ASSETS				
Current assets				
Cash and time deposits	262,037	128,926	-133,111	PBT +33.9 Bn, Plexxikon acquisition -71.3 Bn, Loans / Bonds -18.8 Bn Dividend paid -42.2 Bn, Income taxes paid -31.9 Bn
Trade notes and accounts receivable	205,590	228,505	22,915	
Marketable securities	157,653	191,336	33,683	
Merchandise and finished goods	89,143	109,307	20,164	
Work in process	21,598	24,523	2,925	
Raw materials and supplies	32,050	35,829	3,779	
Deferred tax assets	90,245	93,999	3,754	
Other current assets	38,075	51,252	13,177	
Allowance for doubtful accounts	-2,319	-2,152	167	
Total current assets	894,075	861,530	-32,545	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	119,962	129,330	9,368	
Machinery, equipment and vehicles, net	46,706	48,051	1,345	
Land	38,407	35,688	-2,719	
Construction in progress	20,599	33,660	13,061	
Other, net	12,034	14,512	2,478	
Total property, plant and equipment	237,710	261,242	23,532	Addition of Kitasato Daiichi Sankyo Vaccine (KDSV) +7.9 Bn
Intangible assets				
Goodwill, net	67,316	82,742	15,426	Newly added: Plexxikon +25.6 Bn, KDSV +2.3 Bn
Other intangible assets, net	89,606	150,546	60,940	Newly added: Plexxikon +81.1 Bn, KDSV +2.6 Bn
Total intangible assets	156,923	233,288	76,365	
Investments and other assets				
Investment securities	102,416	104,560	2,144	
Prepaid pension costs	939	—	-939	
Deferred tax assets	73,245	43,186	-30,059	Decrease in loss carried forward due to Daiichi Sankyo non-consolidated net income, etc
Other	15,210	14,978	-232	
Allowance for doubtful accounts	-281	-307	-26	
Total investments and other assets	191,531	162,417	-29,114	
Total non-current assets	586,164	656,949	70,785	
Total assets	1,480,240	1,518,479	38,239	

* All amounts have been rounded down to the nearest million yen

(Millions of yen*)

	Mar 2011	Mar 2012	YoY	Notes
LIABILITIES				
Current liabilities				
Trade notes and accounts payable	58,407	61,824	3,417	
Current portion of convertible bond-type bonds with subscription rights to shares	46,020	—	-46,020	Redeemed in Mar-2011
Short-term bank loans	29,342	71,079	41,737	Change from long-term financing +20.0 Bn
Income taxes payable	7,545	5,313	-2,232	
Allowance for sales returns	1,244	578	-666	
Allowance for sales rebates	1,623	2,928	1,305	
Provision for loss on disaster	4,570	767	-3,803	
Provision for settlement expenses	—	39,138	39,138	Ranbaxy's provision in connection with the investigations by the U.S. Department of Justice
Asset retirement obligations	178	—	-178	
Other current liabilities	158,019	213,335	55,316	
Total current liabilities	306,952	394,965	88,013	
Long-term liabilities				
Bonds payable	100,000	100,000	—	
Long-term debt	124,036	104,000	-20,036	Change to short-term financing -20.0 Bn
Deferred tax liabilities	28,463	52,081	23,618	Tax effect on intangible assets of Plexxikon acquisition +30.8 Bn
Accrued employees' severance and retirement benefits	11,541	10,060	-1,481	
Accrued directors' severance and retirement benefits	155	184	29	
Provision for environment expenses	—	1,246	1,246	
Other long-term liabilities	21,388	23,191	1,803	
Total long-term liabilities	285,585	290,764	5,179	
Total liabilities	592,537	685,729	93,192	
NET ASSETS				
Shareholders' equity				
Common stock	50,000	50,000	—	
Capital surplus	105,194	105,194	—	
Retained earnings	774,274	742,409	-31,865	Net Income +10.4 Bn, Dividend paid -42.2 Bn
Treasury stock, at cost	-14,581	-14,558	23	
Total shareholders' equity	914,888	883,045	-31,843	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	16,559	22,308	5,749	
Deferred gains or losses on hedges	1,193	198	-995	
Foreign currency translation adjustments	-83,636	-100,611	-16,975	Decrease in net assets of overseas subsidiaries in JPY basis -17.0 Bn
Total accumulated other comprehensive income	-65,883	-78,104	-12,221	
Subscription rights to shares	3,544	3,495	-49	
Minority interests	35,153	24,312	-10,841	Investment in KDSV from The Kitasato Institute (49%) +8.2 Bn, Ranbaxy -19.1 Bn
Total net assets	887,702	832,749	-54,953	
Total liabilities and net assets	1,480,240	1,518,479	38,239	

* All amounts have been rounded down to the nearest million yen

10. Consolidated Statements of Cash Flows

(Millions of yen*)

	FY2010 Results	FY2011 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	120,419	33,915	-86,504	
Depreciation	43,945	46,305	2,360	
Loss on impairment of long-lived assets	6,451	7,717	1,266	FY2010: Intangible assets 5.2 Bn, FY2011: Intangible assets 5.9 Bn
Non-recurring depreciation on non-current assets	2,121	—	-2,121	Fukuroi Research Center
Amortization of goodwill	9,148	11,076	1,928	
(Gain) loss on valuation of derivatives	-11,160	16,496	27,656	
Increase (decrease) in allowance for doubtful accounts	837	303	-534	
Increase (decrease) in accrued severance and retirement benefits	558	-1,922	-2,480	
(Increase) decrease in prepaid pension costs	2,297	939	-1,358	
Interest and dividend income	-6,775	-5,514	1,261	
Interest expense	5,519	3,712	-1,807	
Foreign exchange (gains) losses	-35	7,822	7,857	
(Gain) loss on valuation of investment securities	3,550	382	-3,168	
(Gain) loss on sales of investment securities	-2,932	-4,496	-1,564	
(Gain) loss on sales of investments in affiliates	-814	—	814	
(Gain) loss on sales and disposal of property, plant and equipment	-6,066	-5,375	691	
Equity in net (income) losses of affiliated companies	2,645	207	-2,438	
Provision for settlement expenses	—	39,920	39,920	
(Increase) decrease in trade notes and accounts receivable	-1,436	-31,849	-30,413	
(Increase) decrease in inventories	-7,144	-34,255	-27,111	
Increase (decrease) in trade notes and accounts payable	-5,045	7,428	12,473	
Increase (decrease) in accounts payable and accrued expenses	8,921	28,829	19,908	
Other, net	8,301	-821	-9,122	
Subtotal	173,306	120,823	-52,483	
Interest and dividends received	5,465	6,913	1,448	
Interest paid	-2,893	-3,266	-373	
Income taxes paid	-34,738	-31,900	2,838	
Net cash provided by operating activities	141,139	92,569	-48,570	

* All amounts have been rounded down to the nearest million yen

(Millions of yen*)

	FY2010 Results	FY2011 Results	YoY	Notes
Cash flows from investing activities				
Payments into time deposits	-78,456	-73,864	4,592	
Proceeds from maturities in time deposits	48,473	72,566	24,093	
Purchases of marketable securities	-134,752	-142,614	-7,862	
Proceeds from sales of marketable securities	124,587	153,899	29,312	
Acquisitions of property, plant and equipment	-32,250	-54,576	-22,326	
Proceeds from sales of property, plant and equipment	10,082	13,209	3,127	
Acquisitions of intangible assets	-3,882	-9,124	-5,242	
Acquisitions of investment securities	-1,024	-8,741	-7,717	
Proceeds from sales of investment securities	8,790	8,562	-228	
Acquisition of investments in subsidiaries	-1,919	-32	1,887	FY2010: Zenotech
Acquisition of investments in subsidiaries resulting in change in scope of consolidation	-8,254	-71,291	-63,037	FY2010: Roxro, FY2011: Plexxikon
Proceeds from sales of investments in subsidiaries resulting in changes in scope of consolidation	5,641	—	-5,641	Transfer of Shizuoka Factory
Payments for transfer of business	—	-16,096	-16,096	Kitasato Daiichi Sankyo Vaccine (KDSV)
Increase (decrease) in short time loans	1,858	-325	-2,183	
Payment for loans receivable	-27	-1,078	-1,051	
Proceeds from collection of loans receivable	0	0	0	
Other, net	-1,832	4,413	6,245	
Net cash provided by (used in) investing activities	-62,965	-125,095	-62,130	
Cash flows from financing activities				
Net increase (decrease) in short-term bank loans	13,755	22,782	9,027	
Proceeds from long-term debt	7,204	6,967	-237	
Repayments of long-term debt	-4,806	-3,463	1,343	
Redemption of bonds	—	-45,040	-45,040	Redemption of Ranbaxy's Foreign Currency Convertible Bond
Proceeds from stock issuance to minority shareholders	392	11,270	10,878	FY2011: Investment in KDSV from The Kitasato Institute (49%)
Purchases of treasury stock	-34	-12	22	
Proceeds from sale of treasury stock	2	1	-1	
Dividends paid	-42,246	-42,240	6	
Other, net	-247	-464	-217	
Net cash used in financing activities	-25,979	-50,199	-24,220	
Effect of exchange rate changes on cash and cash equivalents	-9,007	-7,003	2,004	
Net increase (decrease) in cash and cash equivalents	43,187	-89,728	-132,915	
Cash and cash equivalents, beginning of period	259,215	302,402	43,187	
Cash and cash equivalents, at end of period	302,402	212,673	-89,729	

* All amounts have been rounded down to the nearest million yen

11. Major R&D Pipeline (Innovative pharmaceuticals)

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage		Remarks
Cardiovascular - Metabolics	DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF) Venous thromboembolism (VTE)	Global Global	P3 P3	Study to be completed in FY2012 Enrollment to be completed in FY2012
	CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome(ACS-MM)	Global	P3	Study results to be presented in 2H 2012 (Study ongoing outside Japan)
				Acute coronary syndrome(ACS-PCI)	JP	P3	Application to be expected in FY2013
				Elective PCI	JP	P3	Application to be expected in FY2013
				Ischemic Stroke	JP	P3	Study to be completed in FY2014
	CS-3150	-	-	Hypertension	-	P1	
	DS-7309	-	-	Diabetes	-	P1	
DS-7250	-	-	Diabetes	-	P1		
Oncology	AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant Giant cell tumor	JP JP	P3 P2	
	ARQ 197	tivatinib	c-Met inhibitor	Non small cell lung cancer	Global	P3	(Study ongoing outside Japan)
				Hepatocellular cancer	US/EU	P2	Study results to be presented at ASCO in June 2012
	CS-1008	tigatuzumab	Anti-DR5 antibody	Colorectal cancer	US/EU	P2	
				Hepatocellular cancer	Global	P2	
	DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P2	
				Non small cell lung cancer	JP	P2	
	CS-7017	efatutazone	PPAR-gamma agonist	Esophageal cancer	JP	P1	
				Non small cell lung cancer	US/EU	P2	
	U3-1287	-	Anti-HER3 antibody	Colorectal cancer	US/EU	P2	
				Non small cell lung cancer	Asia	P1	
	PLX4032	vemurafenib	BRAF inhibitor	Colorectal cancer	JP	P1	
				Non small cell lung cancer	US/EU	P2	
	PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Breast cancer	US	P2	
Thyroid cancer				US/EU	P2		
U3-1565	-	Anti-HB-EGF antibody	Hodgkin lymphoma	US	P2		
DS-2248	-	HSP90 inhibitor	Acute myeloid leukemia	US	P2		
DS-7423	-	PI3K/mTOR inhibitor	Glioblastoma	US	P2		
ARQ 092	-	AKT inhibitor	Solid cancer	US/JP	P1		
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US	P1		
Others	AMG162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Application	Application in Mar 2012
				Rheumatoid arthritis	JP	P2	
	CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP	P3	
				Anti-influenza	US/EU	P1	
	DD-723-B	perflubutane	Ultrasound contrast agent	Contrast enhanced ultrasonography for breast tumor	JP	Application	Application in Dec 2011
				Contrast enhanced ultrasonography for prostate tumor	JP	P3	
	SUN 13834	-	Chymase inhibitor	Atopic Dermatitis	US	P2	
	DS-5565	-	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
	DS-8587	-	-	Antibacterial	-	P1	
CS-4771	-	-	Anti-sepsis	-	P1		
PLX5622	-	-	Rheumatoid arthritis	-	P1		
CS-0777	-	-	Immunomodulator	-	P1		
SUN13837	-	-	Spinal cord injury	-	P1		

Change from announcement in January 2012

■ Change of stage

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Others	AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Application
Cardiovascular - Metabolics	CS-747	prasugrel	Anti-platelet agent	Sickle cell disease	US	P2
Oncology	DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1

■ Discontinue

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Others	SUN11031	human Ghrelin	Appetite stimulation/ Increase gastric motility	Anorexia Nervosa	JP	P3
<Reason for discontinue> Expected goal was not achieved.						

Cardiovascular-Metabolics

[Project after Phase 2]

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DU-176b	edoxaban	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP)
<ul style="list-style-type: none"> • An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates. • An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. • No severe hepatotoxicity signals in pre-clinical and clinical trials • Development by Daiichi Sankyo globally <ul style="list-style-type: none"> - A P3 multi-national trial in AF, completed its patient enrollment in Nov-2010. (ENGAGE AF-TIMI48) - A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism started in Jan-2010.(HOKUSAI VTE) • [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-747	prasugrel	Oral	Anti-platelet agent	Acute coronary syndrome (ACS-MM) Acute coronary syndrome (ACS-PCI) Elective PCI Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient(US, Asia) Efient(EU)
<ul style="list-style-type: none"> • Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan • In June, 2008, a new P3 trial (TRILOGY ACS) started for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM). • A P2 study in pediatric sickle cell disease patients is on-going in US. • [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Efient • [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient • [JP] P3 studies for ACS-PCI, elective PCI and ischemic stroke are on-going. 						

Oncology

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ARQ 197	tivantinib	Oral	c-Met inhibitor	Non small cell lung cancer Hepatocellular cancer Colorectal cancer	ArQule	TBD
<ul style="list-style-type: none"> • c-Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. • Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. • A P3 clinical study for NSCLC is on-going. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	Hepatocellular cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5). • DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells. • Induces apoptosis of tumor cells expressing DR5 on the cell surface. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	CIMYM Biosciences	TBD
<ul style="list-style-type: none"> • A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). • Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-7017	efatutazone	Oral	PPAR-gamma agonist	Non small cell lung cancer Colorectal cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • Inhibits growth of tumor cells in vitro without killing those cells. • Expected to be less toxic compared to standard chemotherapeutics. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
U3-1287	-	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<ul style="list-style-type: none"> • HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins. • HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX4032	vemurafenib	Oral	BRAF inhibitor	Thyroid cancer	Daiichi Sankyo (Plexikon)	Zelboraf
<ul style="list-style-type: none"> • Plexikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche • Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma	Daiichi Sankyo (Plexxikon)	TBD
<ul style="list-style-type: none"> •Plexxikon discovered PLX3397. •Clinical studies are on-going for several types of cancer. 						

Others

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, Treatment / Prophylactic	Daiichi Sankyo	Inavir(JP)
<ul style="list-style-type: none"> • Long-acting neuraminidase inhibitor • Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan • CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. • P3 for the flu prophylactic in Japan • [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
AMG 162	denosumab	Injection	Anti-RANKL antibody	Osteoporosis Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor	Amgen	SRE: Ranmark(JP) Osteoporosis: TBD
<ul style="list-style-type: none"> • Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. • July, 2007 In-licensed from Amgen • Application: Osteoporosis in Mar-2012 • P3 : Breast cancer adjuvant, P2: Rheumatoid arthritis, Giant cell tumor of bone • NDA approval: Skeletal Related Event(SRE) in Jan-2012 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
SUN 13834	-	Oral	Chymase inhibitor	Atopic Dermatitis	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> • Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction. • Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DD-723-B	perflubutane	Injection	Ultrasound contrast agent	Contrast for breast tumor Contrast for prostate tumor	GEHC	Sonazoid(JP)
<ul style="list-style-type: none"> • DD-723-B is marketed in Japan as a brand name of Sonazoid for injection. • Application: Contrast for breast tumor in Dec-2011 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-5565	-	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • An $\alpha 2\delta$ ligand that binds to $\alpha 2\delta$ subunit of voltage-dependent Ca^{2+} channels • Considered to decrease excess Ca^{2+} influx to nerve terminals and to lower pain-related neurotransmitter release. • Clinical studies are on-going for diabetic peripheral neuropathic pain 						

1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

2. Currency Rate (FY2010)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02

3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	201.6	+2.1%	100%	198.8	-4.0%	100%	213.7	-2.4%	100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%	12%	23.2	-11.6%	15%	31.1	-20.6%	1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
Ordinary Income	22%	43.4	+34.8%	12%	23.1	-12.6%	16%	33.7	-12.9%	0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
Net Income	11%	22.3	+122.8%	9%	18.3	+39.4%	12%	26.0	+30.0%	-4%	-7.8	-	7%	58.8	23.9	+68.6%
Ranbaxy Group																
Net sales	100%	54.9	+84.9%	100%	43.8	+20.1%	100%	35.5	-1.4%	100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%	15%	6.6	-1214.7%	2%	0.6	-60.0%	3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%	2%	0.9	-95.4%	16%	5.5	+374.9%	14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
Net Income	33%	18.4	-	10%	4.5	-68.3%	11%	3.8	-	-9%	-3.3	-	14%	23.3	19.1	+456.4%
Inter-segment Transactions																
Net sales		-0.1			-0.1			-0.1			-0.9			-1.2		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
Operating Income		-1.5			-0.7			-1.2			-1.9			-5.4		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
Ordinary Income		-1.5			-1.5			-1.3			-3.9			-8.2		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
Net Income		-7.6			-3.8			-2.2			1.6			-12.0		

4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	256.4	+12.9%	242.5	-0.4%	249.2	-2.3%	219.3	-3.2%	967.4	+1.6%
Japan Company (domestic sales)	105.3	+0.6%	103.0	-1.7%	116.8	-1.4%	91.0	+7.6%	416.0	+0.9%
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
Daiichi Sankyo Healthcare (OTC)	9.3	-2.7%	11.7	-12.9%	13.2	+9.1%	10.6	+23.2%	44.8	+2.6%
Daiichi Sankyo, Inc. (US)	33.6	+1.7%	33.9	+1.2%	34.6	+0.6%	28.4	-11.6%	130.5	-1.9%
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Luitpold Pharmaceuticals, Inc. (US)	14.7	+10.4%	13.7	+1.3%	11.5	-8.5%	14.0	+10.5%	53.9	+3.5%
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
Daiichi Sankyo Europe GmbH	14.8	-14.6%	16.6	-10.0%	18.1	-5.0%	16.9	-17.2%	66.4	-11.7%
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
Asia, South and Central America (ASCA)	5.9	+12.7%	7.1	+12.8%	6.8	+3.3%	7.6	-0.4%	27.4	+6.4%
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
Ranbaxy Laboratories Limited	54.8	+84.7%	43.7	+19.9%	35.4	-1.6%	38.0	-14.5%	171.9	+17.3%
Others	18.0	+25.6%	12.8	-25.1%	12.7	-20.2%	12.8	-20.0%	56.3	-11.1%
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

[Reference] Sales in Local Currency (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	365	+7.6%	394	+10.2%	422	+10.3%	342	-3.3%	1,522	+6.3%
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	160	+16.7%	159	+10.6%	142	+1.2%	168	+20.1%	629	+12.1%
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
Daiichi Sankyo Europe GmbH	126	-3.2%	149	+8.3%	161	+12.1%	150	-7.0%	587	+2.3%
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
Ranbaxy Laboratories Limited	28	+76.3%	21	+17.1%	19	+4.6%	21	-9.0%	89	+18.5%

5. Sales of Global Products (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	60.2	+7.6%	61.4	+3.4%	65.7	+1.6%	54.2	-7.0%	241.5	+1.4%
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
Levofloxacin	17.0	-14.3%	16.9	-28.0%	18.1	-18.3%	17.2	-21.1%	69.1	-20.7%
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
Pravastatin	11.9	-19.1%	11.8	-21.5%	11.6	-21.8%	9.6	-8.3%	44.9	-18.4%
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
Prasugrel (alliance revenue)	0.8	-	1.0	-	1.5	-	2.0	-	5.2	+889.6%
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2011	Amgen	AstraZeneca
Daiichi Sankyo, Inc. (US)					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Daiichi Sankyo Europe GmbH					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly